Incyte is jumping aboard Agenus' antibody discovery platform, signing up to partner on new immuno-oncology drugs with $60 million in cash and promises of up to $350 million in milestones. And the deal news quickly drove up Agenus' shares by more than 30% in premarket trading.
Cerus is up almost 40% in the last month on news of a couple of approvals for its Intercept Blood System to treat blood products. The small cap took advantage of that upswing to raise $70 million to help finance commercialization of the system.
South San Francisco oncology specialist CytomX raised a $20 million C round to advance its in-house pipeline of novel cancer treatments, with partner Pfizer pouring in the lion's share of the new cash.
One of the drug cocktails now in preclinical development for Ebola, ZMapp, has been used for a small group of emergency cases. And now two Scripps investigators have come up with a 3-D model to show where its three antibodies stick to the virus, pointing to new and better therapies as well as informing work on other such cocktail therapies.
The Geneva Foundation, along with partner BioFactura, received a grant of more than $3 million from the U.S. National Institutes of Health to develop an antibody drug to combat the Sudan strain of the ebolavirus.
The drug, a combination of three monoclonal antibodies, has so far been given to 7 patients in the current Ebola outbreak.
A novel biomarker could make it easier for physicians to diagnose rheumatoid arthritis early, thereby improving patients' prospects. The best results come when conventional antibody testing is combined with the new biomarker.
German drug developer MorphoSys is pairing up with Emergent BioSolutions to get its hands on an early-stage prostate cancer treatment, signing a deal worth up to $183 million for a promising antibody.
For William Strohl, the new head of Janssen's Biotechnology Center of Excellence, the future of drug R&D involves novel targets, "fit-for-purpose" antibodies and lots of collaborations.
The Scripps Research Institute has landed a $13 million grant from the National Institute of Allergy and Infectious Diseases to advance antibodies toward the development of an HIV vaccine. Meanwhile, another team of researchers at the University of Nebraska-Lincoln has won nearly $2 million for its experimental HIV vaccine.